• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23537 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Deep anterior lamellar keratoplasty in keratoconus]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Negative pressure wound therapy for wounds healing by secondary intention]
2019     National Institute for Health and Care Excellence (NICE) Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia. NICE technology appraisal guidance 561
2019     Health Information and Quality Authority (HIQA) Clinical and cost-effectiveness of the National Early Warning System (NEWS): a systematic review update. The Irish National Early Warning System (NEWS) National Clinical Guideline No. 1
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Public & philanthropic financial contribution to the development of new drugs: Methodology & 3 Case Studies
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Shoulder prosthesis in complex proximal humeral fractures]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ingenol mebutate (actinic keratosis) - Addendum to Commission A18-55]
2019     National Institute for Health and Care Excellence (NICE) Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma. NICE technology appraisal guidance 562
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) FoundationOne®CDx: genetic profiling of solid tumours
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Implantable cardiac monitors in syncope of unknown etiology]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Axicabtagene ciloleucel (B-cell lymphoma DLBCL) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019     National Institute for Health and Care Excellence (NICE) Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer. NICE technology appraisal guidance 563
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Enzalutamide (Xtandi®) in addition to standard first-line therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC)
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Rapid on-site evaluations of cytological punctures]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Axicabtagene ciloleucel (B-cell lymphoma DLBCL) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019     National Institute for Health and Care Excellence (NICE) Benralizumab for treating severe eosinophilic asthma. NICE technology appraisal guidance 565
2019     NIHR Health Technology Assessment programme Manualised cognitive behavioural therapy in treating depression in advanced cancer: the CanTalk RCT
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Sponsoring of Patient Initiatives in Austria 2018. Update of the Systematic Analyses 2014, 2015 and 2016
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Per-oral endoscopic myotomy (POEM) in achalasia]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Erenumab (prophylaxis of migraine) - Benefit assessment according to §35a Social Code Book V]
2019     National Institute for Health and Care Excellence (NICE) Cochlear implants for children and adults with severe to profound deafness. NICE technology appraisal guidance 566
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pharma: Disclosure of transfers of value in Austria 2018. Update of the systematic analysis 2015
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Optical coherence tomography: usefulness in glaucoma, diabetic retinopathy and age-related macular degeneration]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abemaciclib in combination with an aromatase inhibitor (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2019     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of strategies to prevent urinary tract infections related to urethral catheters in critically ill patients in intensive care units]
2019     National Institute for Health and Care Excellence (NICE) Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies. NICE technology appraisal guidance 567
2019     NIHR Health Technology Assessment programme Cabozantinib and vandatinib for treating advanced or metastatic medullary thyroid cancer (ID56)
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pembrolizumab (Keytruda®) as first-line therapy for PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (NSCLC)
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Video head impulse test in vertigo]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abemaciclib in combination with fulvestrant (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2019     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evidence on the personalization of population-based breast cancer screening]
2019     National Institute for Health and Care Excellence (NICE) Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal). NICE technology appraisal guidance 568
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Screening programs for children and adolescents from 6 to 18 years. Results on selected countries, Austrian screening programmes and recommendations from evidence-based guidelines
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Palivizumab for the prevention of respiratory syncytial virus lower respiratory tract infections]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alirocumab (primary hypercholesterolaemia or mixed dyslipidaemia) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2019     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Cerenkov lluminescence imaging system for intraoperative assessment of surgical margins in breast, prostate, and gastrointestinal cancer]
2019     National Institute for Health and Care Excellence (NICE) Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer. NICE technology appraisal guidance 569
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Rehabilitation for children and adolescents in Austria: A systematic analysis of evaluation methodologies
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Sacral nerve stimulation/neuromodulation in bladder and/or bowel incontinence]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Semaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2019     Agency for Healthcare Research and Quality (AHRQ) Long-term drug therapy and drug holidays for osteoporosis fracture prevention: a systematic review
2019     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [MALDI-TOF mass spectrometry technology in the diagnosis of antibiotic resistance]
2019     National Institute for Health and Care Excellence (NICE) Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 570
2019     NIHR Health Technology Assessment programme An evaluation of the feasibility of conducting a randomised clinical trial to evaluate the clinical and cost-effectiveness of a more permissive temperature threshold for antipyretic intervention in critically ill children with fever due to infection: the FEVER feasibility study
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Cervical Carcinoma Prevention - Implementation of an HPV screening test for early detection of cervical cancer in Austria
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge, state of practice: Use of direct oral anticoagulants and warfarin in the context of atrial fibrillation and venous thromboembolism]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Eposterior tibial nerve stimulation in overactive bladder and bowel incontinence]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tofacitinib (psoriatic arthritis) - Addendum to Commission A18-51]
2019     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Economic, organization and safety impact of drug robotic dispensing in Spanish hospitals]
2019     National Institute for Health and Care Excellence (NICE) Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib. NICE technology appraisal guidance 571
2019     NIHR Health Technology Assessment programme Interferon gamma release assays for Diagnostic Evaluation of Active tuberculosis (IDEA): test accuracy study and economic evaluation
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) POCT/ Point of Care Tests: D-Dimer and Troponin
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [National medical protocols and associated prescriptions: anticoagulant therapy]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Pelvic vein embolization or sclerotherapy in pelvic congestion syndrome]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (melanoma) -Addendum to Commission A18-53]
2019     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Powder bed fusion manufacturing of titanium for customized bone replacements in craneomaxillofacial reconstruction]
2019     National Institute for Health and Care Excellence (NICE) Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes. NICE technology appraisal guidance 572
2019     Medical Services Advisory Committee (MSAC) Digital breast tomosynthesis
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Minimum volume standards for quality assurance in day surgery: Fundamentals and Systematic Review
2019     Penn Medicine Center for Evidence-based Practice (CEP) Pulmonary Artery Catheters Catheter Dwell Time and Routine Replacement
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tildrakizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V]
2019     National Institute for Health and Care Excellence (NICE) Certolizumab pegol for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 574
2019     NIHR Health Technology Assessment programme Early versus deferred endovenous ablation of superficial venous reflux in patients with venous ulceration: the EVRA RCT
2019     Penn Medicine Center for Evidence-based Practice (CEP) Dual Antiplatelet Therapy Following Revascularization for Peripheral Artery Disease
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Lenvatinib for iodine-refractory differentiated thyroid cancer]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fluticasone furoate/umeclidinium/vilanterol (COPD) - Benefit assessment according to §35a Social Code Book V]
2019     National Institute for Health and Care Excellence (NICE) Tildrakizumab for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 575
2019     NIHR Health Technology Assessment programme Electronically delivered interventions to reduce antibiotic prescribing for respiratory infections in primary care: cluster RCT using electronic health records and cohort study
2019     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Irreversible electroporation for the treatment of liver and pancreatic cancer]
2019     Penn Medicine Center for Evidence-based Practice (CEP) Dosing of Botulinum Toxin for Neurologic Indications
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2019     National Institute for Health and Care Excellence (NICE) Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal). NICE technology appraisal guidance 576
2019     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) Diagnostic accuracy and clinical utility of PET/CT amyloid in mild cognitive impairment
2019     Andalusian Health Technology Assessment Area (AETSA) Genetic diseases in Spain. Map of genetic test available in the National Health System. Upgrade.
2019     Penn Medicine Center for Evidence-based Practice (CEP) Management of Tunneled Dialysis Catheters in Patients with Bloodstream Infection
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tezacaftor/ivacaftor (cystic fibrosis) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019     Agency for Healthcare Research and Quality (AHRQ) Management of infertility
2019     National Institute for Health and Care Excellence (NICE) Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma. NICE technology appraisal guidance 577
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [National medical protocols and associated prescriptions: antidiabetics]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (cystic fibrosis) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019     National Institute for Health and Care Excellence (NICE) Enzalutamide for hormone-relapsed non-metastatic prostate cancer. NICE technology appraisal guidance 580
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: autonomy in intellectually disabled young people aged 6 to 21 years]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V]
2019     National Institute for Health and Care Excellence (NICE) Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes. NICE technology appraisal guidance 583
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: axicabtagene ciloleucel for the treatment of relapsed or refractory large B-cell lymphoma]
2019     Agency for Care Effectiveness (ACE) Botulinum toxin A for the management of focal spasticity of the upper limbs associated with stroke in adults
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V]
2019     National Institute for Health and Care Excellence (NICE) Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer. NICE technology appraisal guidance 584
2019     Agency for Care Effectiveness (ACE) Ticagrelor for preventing thrombotic events in adults with acute coronary syndromes
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Insulin degludec (diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2019     National Institute for Health and Care Excellence (NICE) Ocrelizumab for treating primary progressive multiple sclerosis. NICE technology appraisal guidance 585
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) - Addendum to Commission A18-66]
2019     National Institute for Health and Care Excellence (NICE) Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib. NICE technology appraisal guidance 586
2019     NIHR Health Technology Assessment programme Tranexamic acid to improve functional status in adults with spontaneous intracerebral haemorrhage: the TICH-2 RCT
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dabrafenib (melanoma) - Addendum to Commission A18-59]
2019     National Institute for Health and Care Excellence (NICE) Lenalidomide plus dexamethasone for previously untreated multiple myeloma. NICE technology appraisal guidance 587
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trametinib (melanoma) - Addendum to Commission A18-60]
2019     National Institute for Health and Care Excellence (NICE) Nusinersen for treating spinal muscular atrophy. NICE technology appraisal guidance 588
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (hepatocellular carcinoma) - Addendum to Commission A18-57]
2019     National Institute for Health and Care Excellence (NICE) Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity. NICE technology appraisal guidance 589